Company logo

LXRX - Lexicon Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
The Woodlands, United States
Type: Equity

LXRX price evolution
LXRX
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $35.62 $96.49 $22.46
Short term investments $274.35 $259.1 $147.56
Net receivables $2.9 $2.62 $1.53 $1.01
Inventory $0.64 $0.58 $0.51 $0.38
Total current assets $268.61 $320.84 $364.65 $176.55
Long term investments
Property, plant & equipment $7.15 $7.14 $7.2 $7.51
Goodwill & intangible assets $44.54 $44.54 $44.54
Total noncurrent assets $52.51 $52.57 $52.88
Total investments $274.35 $259.1 $147.56
Total assets $321.12 $373.36 $417.22 $229.43
Current liabilities
Accounts payable $14.2 $12.22 $8.07 $14.39
Deferred revenue
Short long term debt
Total current liabilities $36.05 $27.88 $23.4 $31.55
Long term debt $99.89 $99.5 $104.95 $104.77
Total noncurrent liabilities $105.5 $104.95 $104.77
Total debt $99.5 $104.95 $104.77
Total liabilities $142.61 $133.38 $128.35 $136.32
Shareholders' equity
Retained earnings -$1933.48 -$1868.66 -$1815.24 -$1766.84
Other shareholder equity $0.35 -$0.19 -$0.05 $0.03
Total shareholder equity $239.98 $288.87 $93.11
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $22.46 $46.34 $64.06 $126.26
Short term investments $147.56 $92.01 $22.68 $26.01
Net receivables $1.01 $0.03 $0.01 $0.4
Inventory $0.38
Total current assets $176.55 $140.87 $88.92 $157.72
Long term investments
Property, plant & equipment $7.51 $4.37 $1.18 $0.29
Goodwill & intangible assets $44.54 $44.54 $44.54 $44.54
Total noncurrent assets $52.88 $53.43 $47.99 $46.07
Total investments $147.56 $92.01 $22.68 $26.01
Total assets $229.43 $194.3 $136.91 $203.79
Current liabilities
Accounts payable $14.39 $10.39 $9.15 $5.47
Deferred revenue
Short long term debt $11.65
Total current liabilities $31.55 $23.17 $22.12 $46.81
Long term debt $104.77 $48.58
Total noncurrent liabilities $104.77 $54 $1.19 $0.61
Total debt $104.77 $54 $11.65
Total liabilities $136.32 $77.17 $23.31 $47.42
Shareholders' equity
Retained earnings -$1766.84 -$1589.72 -$1487.78 -$1400.02
Other shareholder equity $0.03 -$0.43 -$0.01 -$0.01
Total shareholder equity $93.11 $117.12 $113.59 $156.37
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $1.75 $1.65 $1.13 $0.7
Cost of revenue $0.17 $0.03 $0.07
Gross Profit $1.68 $1.48 $1.1 $0.63
Operating activities
Research & development $17.64 $14.37 $14.76
Selling, general & administrative $39.19 $32.06 $32.61
Total operating expenses $65.37 $56.84 $46.43 $47.37
Operating income -$55.35 -$45.33 -$46.74
Income from continuing operations
EBIT -$51.22 -$43.45 -$44.34
Income tax expense
Interest expense -$4.56 $2.21 $4.95 $5.42
Net income
Net income -$64.81 -$53.43 -$48.4 -$49.76
Income (for common shares) -$53.43 -$48.4 -$49.76
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $1.2 $0.14 $0.3 $24
Cost of revenue $0.09 $1.93
Gross Profit $1.12 $0.14 $0.3 $22.07
Operating activities
Research & development $58.89 $52.82 $55.05 $153.62
Selling, general & administrative $113.98 $48.08 $32.34 $47.23
Total operating expenses $172.87 $100.9 $87.39 $69.87
Operating income -$171.75 -$100.76 -$87.09 -$47.8
Income from continuing operations
EBIT -$164.02 -$99.16 -$86.96 -$44.03
Income tax expense
Interest expense $13.1 $2.78 $0.8 $14.54
Net income
Net income -$177.12 -$101.94 -$87.76 -$58.57
Income (for common shares) -$177.12 -$101.94 -$87.76 -$58.57
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$53.43 -$48.4 -$49.76
Operating activities
Depreciation $0.14 $0.14 $0.15
Business acquisitions & disposals
Stock-based compensation $4.86 $4.3 $3.21
Total cash flows from operations -$48.54 -$55.13 -$50.55
Investing activities
Capital expenditures -$0.25
Investments -$12.07 -$110.22 $51.9
Total cash flows from investing -$69.08 -$12.32 -$110.22 $51.9
Financing activities
Dividends paid
Sale and purchase of stock $0 -$1.64
Net borrowings -$0
Total cash flows from financing $238.45 -$0.01 $239.38 -$0
Effect of exchange rate
Change in cash and equivalents $12.09 -$60.88 $74.03 $1.35
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$177.12 -$101.94 -$87.76 -$58.57
Operating activities
Depreciation $0.55 $0.43 $0.29 $2.93
Business acquisitions & disposals $160.38
Stock-based compensation $14.34 $11.52 $10.58 $13.27
Total cash flows from operations -$161.9 -$88.85 -$87.02 -$142.97
Investing activities
Capital expenditures -$0.47 -$1.33 -$1.22 $10.93
Investments -$49.47 -$69.75 $3.33 $209.44
Total cash flows from investing -$49.94 -$71.08 $2.11 $380.76
Financing activities
Dividends paid
Sale and purchase of stock $138 $93.34 $34.41 $68.94
Net borrowings $49.96 $48.87 -$11.7 -$216.58
Total cash flows from financing $187.96 $142.21 $22.71 -$147.64
Effect of exchange rate
Change in cash and equivalents -$23.88 -$17.72 -$62.2 $90.15
Fundamentals
Market cap $256.66M
Enterprise value N/A
Shares outstanding 361.49M
Revenue $5.23M
EBITDA N/A
EBIT N/A
Net Income -$216.39M
Revenue Q/Q 980.25%
Revenue Y/Y 884.75%
P/E ratio -1.19
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 49.08
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.60
ROA -64.54%
ROE N/A
Debt/Equity 1.46
Net debt/EBITDA N/A
Current ratio 7.45
Quick ratio 7.43